Market Place
Sourcing Support
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
24 May 2024 //
GLOBENEWSWIRE
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Number of voting rights as of March 31, 2024
02 Apr 2024 //
GLOBENEWSWIRE
Results from Mont Blanc Phase 3 Trial of Nicox`s NCX 470 in Glaucoma
20 Mar 2024 //
GLOBENEWSWIRE
Number of votings rights as of January 31 2024
01 Feb 2024 //
GLOBENEWSWIRE
Number of voting rights as of November 30, 2023
01 Dec 2023 //
GLOBENEWSWIRE
Number of voting rights as of April 30, 2023
03 May 2023 //
GLOBENEWSWIRE
Transfer of Nicoxâ shares to Euronext Growth Paris effective on April 28, 2023
26 Apr 2023 //
GLOBENEWSWIRE
New Data on Two Nicoxâ Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
26 Apr 2023 //
GLOBENEWSWIRE
Nicox Provides First Quarter 2023 Financial and Business Highlights
19 Apr 2023 //
GLOBENEWSWIRE
Nicox: Ordinary Shareholder Meeting of Feb28, 2023 - Approval of all Resolutions
01 Mar 2023 //
GLOBENEWSWIRE
Number of voting rights as of February 28, 2023
01 Mar 2023 //
GLOBENEWSWIRE
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
06 Jan 2023 //
GLOBENEWSWIRE
Number of voting rights as of December 31, 2022
03 Jan 2023 //
GLOBENEWSWIRE
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod
11 Dec 2020 //
NEWS
Nicox and Fera Pharmaceuticals Focus on Rare Disease Indication for Naproxcinod
26 Sep 2018 //
GLOBENEWSWIRE
FDA Panel Nixes Naproxcinod for Osteoarthritis
16 May 2017 //
MEDSCAPE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.